Literature DB >> 25879629

Pentoxifylline Attenuates Proteinuria in Anti-Thy1 Glomerulonephritis via Downregulation of Nuclear Factor-κB and Smad2/3 Signaling.

Yung-Ming Chen1,2, Wen-Chih Chiang1, Yalin Yang1, Chun-Fu Lai1, Kwan-Dun Wu1, Shuei-Liong Lin1.   

Abstract

Anti-Thy1 glomerulonephritis is a rat nephritis model closely simulating human mesangial proliferative glomerulonephritis. It affects primarily the mesangium, yet displays substantial proteinuria during the course. This study investigated the molecular signals underlying proteinuria in this disease and the modulation of which by the known antiproteinuric agent, pentoxifylline. Male Wistar rats were randomly divided into a control group and nephritic groups with or without treatment with IMD-0354 (an IκB kinase inhibitor), SB431542 (an activin receptor-like kinase inhibitor) or pentoxifylline. Kidney sections were prepared for histological examinations. Glomeruli were isolated for mRNA and protein analysis. Urine samples were collected for protein and nephrin quantitation. One day after nephritis induction, proteinuria developed together with ultrastructural changes of the podocyte and downregulation of podocyte mRNA and protein expression. These were associated with upregulation of tumor necrosis factor (TNF)-α and transforming growth factor (TGF)-β/activins mRNAs and activation of nuclear factor (NF)-κB p65 and Smad2/3. IMD-0354 attenuated proteinuria on d 1, whereas SB431542 decreased proteinuria on d 3 and 5, in association with partial restoration of downregulated podocyte mRNA and protein expression. Pentoxifylline attenuated proteinuria and nephrinuria through the course, plus inhibition of p-NF-κB p65 (d 1) and p-Smad2/3 (d 5) and partial reversal of downregulated podocyte mRNA and protein. Our data show that the pathogenesis of proteinuria in anti-Thy1 glomerulonephritis involves TNF-α and TGF-β/activin pathways, and the evolution of this process can be attenuated by pentoxifylline via downregulation of NF-κB and Smad signals and restoration of the podocyte component of the glomerular filtration barrier.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25879629      PMCID: PMC4503651          DOI: 10.2119/molmed.2015.00023

Source DB:  PubMed          Journal:  Mol Med        ISSN: 1076-1551            Impact factor:   6.354


  48 in total

Review 1.  The podocyte's response to injury: role in proteinuria and glomerulosclerosis.

Authors:  S J Shankland
Journal:  Kidney Int       Date:  2006-05-10       Impact factor: 10.612

2.  Inhibition of gene markers of fibrosis with a novel inhibitor of transforming growth factor-beta type I receptor kinase in puromycin-induced nephritis.

Authors:  Eugene T Grygielko; William M Martin; Christopher Tweed; Peter Thornton; John Harling; David P Brooks; Nicholas J Laping
Journal:  J Pharmacol Exp Ther       Date:  2005-03-15       Impact factor: 4.030

3.  Use of pentoxifylline in membranous nephropathy.

Authors:  D Ducloux; C Bresson-Vautrin; J Chalopin
Journal:  Lancet       Date:  2001-05-26       Impact factor: 79.321

4.  Pentoxifylline attenuates experimental mesangial proliferative glomerulonephritis.

Authors:  Y M Chen; C T Chien; M I Hu-Tsai; K D Wu; C C Tsai; M S Wu; T J Tsai
Journal:  Kidney Int       Date:  1999-09       Impact factor: 10.612

5.  Effect of pentoxifylline in addition to losartan on proteinuria and GFR in CKD: a 12-month randomized trial.

Authors:  Shuei-Liong Lin; Yung-Ming Chen; Wen-Chih Chiang; Kwan-Dun Wu; Tun-Jun Tsai
Journal:  Am J Kidney Dis       Date:  2008-07-09       Impact factor: 8.860

6.  Gene therapy by skeletal muscle expression of decorin prevents fibrotic disease in rat kidney.

Authors:  Y Isaka; D K Brees; K Ikegaya; Y Kaneda; E Imai; N A Noble; W A Border
Journal:  Nat Med       Date:  1996-04       Impact factor: 53.440

7.  TbetaRI independently activates Smad- and CD2AP-dependent pathways in podocytes.

Authors:  Sandhya Xavier; Thiruvur Niranjan; Stefanie Krick; Taoran Zhang; Wenjun Ju; Andrey S Shaw; Mario Schiffer; Erwin P Böttinger
Journal:  J Am Soc Nephrol       Date:  2009-08-13       Impact factor: 10.121

8.  Neutralization of TGF-beta by anti-TGF-beta antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice.

Authors:  K Sharma; Y Jin; J Guo; F N Ziyadeh
Journal:  Diabetes       Date:  1996-04       Impact factor: 9.461

9.  The monocyte chemoattractant protein-1/cognate CC chemokine receptor 2 system affects cell motility in cultured human podocytes.

Authors:  Davina Burt; Gennaro Salvidio; Elena Tarabra; Federica Barutta; Silvia Pinach; Patrizia Dentelli; Giovanni Camussi; Paolo Cavallo Perin; Gabriella Gruden
Journal:  Am J Pathol       Date:  2007-11-30       Impact factor: 4.307

10.  Synergistic effect of mesangial cell-induced CXCL1 and TGF-β1 in promoting podocyte loss in IgA nephropathy.

Authors:  Li Zhu; Qingxian Zhang; Sufang Shi; Lijun Liu; Jicheng Lv; Hong Zhang
Journal:  PLoS One       Date:  2013-08-30       Impact factor: 3.240

View more
  4 in total

1.  The role of transcriptional factor D-site-binding protein in circadian CCL2 gene expression in anti-Thy1 nephritis.

Authors:  Yang Lu; Yan Mei; Lei Chen; Lingling Wu; Xu Wang; Yingjie Zhang; Bo Fu; Xizhao Chen; Yuansheng Xie; Guangyan Cai; Xueyuan Bai; Qinggang Li; Xiangmei Chen
Journal:  Cell Mol Immunol       Date:  2018-03-22       Impact factor: 11.530

2.  Pentoxifylline Alleviates Early Brain Injury After Experimental Subarachnoid Hemorrhage in Rats: Possibly via Inhibiting TLR 4/NF-κB Signaling Pathway.

Authors:  Da-Yong Xia; Hua-Sheng Zhang; Ling-Yun Wu; Xiang-Sheng Zhang; Meng-Liang Zhou; Chun-Hua Hang
Journal:  Neurochem Res       Date:  2016-12-08       Impact factor: 3.996

3.  Nitric oxide mediates prolyl hydroxylase 3 expression in mesangial cells and in glomerulonephritis.

Authors:  Ahmed Aglan; Sebastian Longen; Nathalie Dehne; Yvette Köhler; Mohamed Hassan; Martina Beck; Claudia Tredup; Meike Boosen; Tzung-Harn Louise Hsieh; Liliana Schaefer; Karl-Friedrich Beck; Josef Pfeilschifter
Journal:  J Mol Med (Berl)       Date:  2017-01-04       Impact factor: 4.599

Review 4.  Therapeutic efficacy of pentoxifylline on proteinuria and renal progression: an update.

Authors:  Yung-Ming Chen; Wen-Chih Chiang; Shuei-Liong Lin; Tun-Jun Tsai
Journal:  J Biomed Sci       Date:  2017-11-13       Impact factor: 8.410

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.